Updates from the 2023 American Society of Hematology Annual Meeting

The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 318 LRF-affiliated scientists, including past and present members of LRF’s world-leading Scientific Advisory Board (SAB) and grantees, contributing to an abstract presented at the conference.

Widely regarded as the premier event in malignant and nonmalignant hematology, the ASH Meeting provides a critical forum for leading hematologists/oncologists to present their findings to over 20,000 of their peers. Among the distinguished scientists attending, more than 100 LRF-affiliated scientists presented at the 2023 ASH Annual Meeting.

In addition to LRF’s representation through presentations, LRF researchers contributed to 859 abstracts across all hematology and 651 lymphoma-related abstracts. 85 percent of LRF scholars – participants in LRF’s Lymphoma Scientific Research Mentoring Program (LSRMP) – authored at least one abstract at ASH.

Highlights from ASH 2023:

• MRD Status Predicts Progression-free Survival Outcomes in Follicular Lymphoma
• Barriers Identified to the Use of CAR T-cell Therapy in Non-Hodgkin Lymphoma
• Total Lifetime Costs of Treating Chronic Lymphocytic Leukemia Are High
• High Complete Response Rates in High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Loncastuximab Tesirine
• Overall Survival in Mantle Cell Lymphoma Has Improved in Era of Targeted Therapies
• Durable Responses Observed with Valemetostat Tosylate Treatment in Relapsed/Refractory Peripheral T-Cell Lymphoma
• Durable Responses Observed with Valemetostat Improved Outcomes in Second-Line Treatment of Large B-Cell Lymphoma in the Era of CAR T-cell Therapies
• Increased Metabolism in High IRF4-Expressing Lymphoma Cells Limits the Availability of Glucose in the Tumor Microenvironment